Published in Cancer Weekly, June 8th, 1998
Researchers from the U.S. National Cancer Institute (NCI)/National Institutes of Health (NIH), Bethesda, Maryland, treated a consecutive series of 1241 metastatic cancer patients with high-dose bolus infusions of IL-2 at the NCI between January 1, 1985 and January 1, 1997.
Udai S. Kammula presented results for his NCI colleagues at the 34th Annual Meeting of the American Society of Clinical Oncology, held May 16-19, 1998, in Los Angeles, California (abstract "Trends in the Safety of Administration of High-dose Interleukin-2 in Patients with Metastatic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.